FACT-CRT: Factors Associated with Response to Cardiac Resynchronization Therapy in Heart Failure Patients with Non-LBBB ECG Pattern
Brief description of study
This research study seeks to validate how
echocardiogram (echo) data predicts response to cardiac resynchronization
therapy (CRT) provided by a CRT device with a defibrillator (CRT-D) in individuals
without the heart arrhythmia abnormality left bundle branch block (LBBB). It
also aims to identify new variables recorded from electrocardiograms (ECG) or
echocardiography to improve use of CRT in patients with heart failure.
Detailed description of study
Consented participants must first complete a 20-minute ECG
recording, and the study team will record their echo data before CRT-D implant.
The echo data can be from any echo done within 1 year prior to CRT-D implant.
After enrollment, the study team collects data about the
procedure and the implanted device. They will reach out to participants via
phone every 6 months to collect medical information and data from their device.
Participation in this study lasts for about 48 months.
Eligibility of study
You may be eligible for this study if you meet the following criteria:
-
Conditions:
Heart Failure (HF)
-
Age: Between 18 Years - 100 Years
-
Gender: All
Inclusion Criteria:
- Receiving optimal medical therapy for heart failure
- Successful CRT-D generator implant
- Meet other specific heart failure criteria
Exclusion Criteria:
- Unable to obtain imaging data from echo within 1 year prior to CRT-D implant
- Unable
to obtain the 20-minute ECG prior to CRT-D implant
- Unable
to enroll within 14 days following successful CRT-D generator implant
- Unable
or unwilling to follow the study protocol
- Less
than 24 months life expectancy at enrollment
- Pregnancy
or planned pregnancy in the next 24 months
Updated on
09 Mar 2024.
Study ID: 2021-76
If you need assistance finding a non-cancer clinical research study or if you have any questions, please email psom-ocr@pobox.upenn.edu
For cancer trials contact EmergingMed: 1-855-216-0098 or PennCancerTrials@emergingmend.com
